Literature DB >> 9569301

Urinary excretion of orally ingested gastrografin on CT.

S Apter1, G Gayer, M Amitai, M Hertz.   

Abstract

Renal excretion of orally ingested gastrografin has rarely been reported on computed tomography (CT). We studied the unenhanced scans of 82 patients with bowel disorders or perforation to assess the prevalence of urinary contrast material (CM) in various bowel diseases. We also assessed the clinical significance of this sign. In addition, we reviewed the unenhanced CT scans of 100 randomly selected patients without bowel diseases as a control group. Twenty-nine of the 58 patients with bowel diseases, six of nine with free perforation, and one of 15 with covered perforation had CM in the urinary tract. None of the 100 without bowel disease showed urinary CM. Statistical analysis was done by using the Fisher's exact test. The prevalence of urinary CM was highest in inflammatory bowel disease, radiation enteritis, and free perforation (p < 0. 0001). This study shows that the CT finding of orally ingested gastrografin in the urinary tract differentiates patients with bowel disease from those without.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9569301     DOI: 10.1007/s002619900344

Source DB:  PubMed          Journal:  Abdom Imaging        ISSN: 0942-8925


  3 in total

1.  Vicarious urinary excretion of iodinated contrast in a Crohn's patient.

Authors:  Hooman Yarmohammadi; Esben Vogelius; Mariana Meyers; Nami Azar
Journal:  J Radiol Case Rep       Date:  2010-02-01

2.  Absorption of L-lysine diatrizoate from the gastrointestinal tract: the effect of surgery, inflammation, and neoplasia.

Authors:  Werner Golder; Gerhard Dietz; Klaus Rittinghaus; Peter Weinberg; Michael Jarosch
Journal:  Int J Colorectal Dis       Date:  2003-04-02       Impact factor: 2.571

3.  CT in the clinical and prognostic evaluation of acute graft-vs-host disease of the gastrointestinal tract.

Authors:  A Shimoni; U Rimon; M Hertz; R Yerushalmi; M Amitai; O Portnoy; L Guranda; A Nagler; S Apter
Journal:  Br J Radiol       Date:  2011-11-29       Impact factor: 3.039

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.